Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29624374 | 1.00 | HPGD (0.55) | HPGDLMNAKMT2AMEN1IGF1R | |
| SCHEMBL2799632 | 0.88 | PRKDC (0.42) | HPGDLMNAKMT2AMEN1IGF1R | |
| SCHEMBL30286495 | 0.88 | PRKDC (0.42) | HPGDLMNAKMT2AMEN1IGF1R | |
| SCHEMBL9860604 | 0.85 | LMNA (0.54) | HPGDLMNAKMT2AMEN1IGF1R | |
| SCHEMBL14070022 | 0.84 | LMNA (0.64) | HPGDLMNAKMT2AMEN1IGF1R | |
| SCHEMBL15152237 | 0.84 | SMN1; SMN2 (0.51) | HPGDLMNAKMT2AMEN1IGF1R | |
| SCHEMBL15152345 | 0.84 | PRKDC (0.40) | HPGDLMNAKMT2AMEN1IGF1R | |
| SCHEMBL28110562 | 0.84 | ALDH1A1 (0.50) | HPGDLMNAKMT2AMEN1IGF1R | |
| Ethylene SCHEMBL6616812 | 0.80 | LMNA (0.44) | HPGDLMNAKMT2AMEN1IGF1R | |
| SCHEMBL22133239 | 0.79 | LMNA (0.55) | HPGDLMNAKMT2AMEN1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119606947-A | Preparation method and application of chromone compound | 广西民族大学 | 2025-03-14 | — | — | CN | claimed |
| CN-119462675-A | Topoisomerase I/II double-target inhibitor and preparation method and application thereof | 四川大学华西医院 | 2025-02-18 | — | — | CN | claimed |
| CN-119462676-A | Topoisomerase II inhibitor and preparation method and application thereof | 四川大学华西医院 | 2025-02-18 | — | — | CN | claimed |
| CN-117069732-B | Preparation method of benzo [ c ] phenanthridine natural product and derivative thereof | 沈阳药科大学 | 2024-04-26 | — | — | CN | claimed |
| CN-117069732-A | Preparation method of benzo [ c ] phenanthridine natural product and derivative thereof | 沈阳药科大学 | 2023-11-17 | — | — | CN | claimed |
| CN-114773354-B | Simple synthesis method of Trisphaeridine | 武汉理工大学 | 2023-03-24 | — | — | CN | claimed |
| CN-114773354-A | Simple synthesis method of Trisphaeridine | 武汉理工大学 | 2022-07-22 | — | — | CN | claimed |
| CN-116655582-B | Synthesis method and application of sanguinarine intermediate compound bromo-compound | 宁波九胜创新医药科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12606538-B2 | Benzo[b]selenophene sting regulator, preparation method and use thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-04-21 | — | — | US | disclosed |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | UCB Biopharma SRL (BE) | 2026-03-17 | — | — | US | disclosed |
| US-20260062399-A1 | SUBSTITUTED ETHYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVES | ENVERIC BIOSCIENCES CANADA INC (CA) | 2026-03-05 | — | — | US | disclosed |
| EP-4081296-B1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB Biopharma SRL (BE) | 2026-02-11 | — | — | EP | disclosed |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-09 | — | — | US | disclosed |
| US-5488134-A | Preparation of compounds of lignan series | SHIONOGI & CO., LTD. (JP) | 1996-01-30 | — | — | US | disclosed |
| US-5449814-A | Dehydration; Michael condensation | SHIONOGI & CO., LTD. (JP) | 1995-09-12 | — | — | US | disclosed |
| US-5420333-A | Hydroxy ketone compounds | SHIONOGI & CO., LTD. (JP) | 1995-05-30 | — | — | US | disclosed |
| EP-0646570-A1 | PROCESS FOR PRODUCING LIGNAN COMPOUND | SHIONOGI & CO., LTD. (JP) | 1995-04-05 | — | — | EP | disclosed |
| EP-0597107-A1 | LIGNAN ANALOG, PRODUCTION THEREOF, AND HYPOLIPIDEMIC DRUG | SHIONOGI & CO., LTD. (JP) | 1994-05-18 | — | — | EP | disclosed |
| US-4328227-A | HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-05-04 | — | — | US | disclosed |
| US-4048171-A | 1,4-Dihydropyridines | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606538-B2 | Benzo[b]selenophene sting regulator, preparation method and use thereof | STING1, IRF3, TLR7 | HPGD 2808/4885LMNA 2008/4885KMT2A 4236/4885 |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | FCGR2A, FCER2, FCGR1A | HPGD 1345/4885LMNA 3611/4885KMT2A 1500/4885 |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC1 | HPGD 611/4885LMNA 4394/4885KMT2A 4805/4885 |
| US-20260062399-A1 | SUBSTITUTED ETHYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVES | HTR1D, ADRA1D, CHRM1 | HPGD 1900/4885LMNA 2264/4885KMT2A 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.